Novavax, Inc. $NVAX Shares Acquired by First Trust Advisors LP

First Trust Advisors LP increased its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 37.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 409,328 shares of the biopharmaceutical company’s stock after purchasing an additional 112,009 shares during the period. First Trust Advisors LP’s holdings in Novavax were worth $3,332,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. KBC Group NV raised its position in Novavax by 34.9% in the first quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 1,229 shares during the period. Legal & General Group Plc boosted its position in shares of Novavax by 1.0% in the third quarter. Legal & General Group Plc now owns 155,743 shares of the biopharmaceutical company’s stock worth $1,350,000 after buying an additional 1,529 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Novavax by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,617 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Novavax by 2.3% in the second quarter. The Manufacturers Life Insurance Company now owns 78,048 shares of the biopharmaceutical company’s stock valued at $492,000 after buying an additional 1,718 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in shares of Novavax by 6.4% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 34,663 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 2,100 shares in the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Price Performance

NASDAQ:NVAX opened at $7.74 on Friday. The firm has a 50-day moving average of $8.79 and a two-hundred day moving average of $8.98. The stock has a market cap of $1.27 billion, a P/E ratio of -13.34 and a beta of 2.46. Novavax, Inc. has a 1-year low of $6.20 and a 1-year high of $11.97.

Novavax (NASDAQ:NVAX) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. Novavax had a negative return on equity of 14.82% and a negative net margin of 14.73%.The business had revenue of $56.70 million for the quarter, compared to analyst estimates of $52.51 million. During the same period in the previous year, the company earned $0.62 earnings per share. The company’s revenue for the quarter was down 76.2% compared to the same quarter last year. As a group, equities analysts expect that Novavax, Inc. will post -0.19 earnings per share for the current year.

Key Headlines Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported second-quarter revenue of $56.7 million, exceeding the approximately $52.5 million consensus estimate, while its adjusted loss of $0.32 per share was narrower than analysts expected. Novavax Q2 earnings report
• Positive Sentiment: The company increased its full-year 2026 adjusted revenue framework to $235 million–$275 million from $230 million–$270 million, supported by licensing and milestone-related revenue. Novavax raises 2026 revenue outlook after Q2 beat
• Positive Sentiment: Novavax improved its combined GAAP research and development plus selling, general and administrative expense guidance by $10 million at the midpoint, reinforcing its cost-reduction strategy. It ended June with approximately $724 million in cash, cash equivalents, marketable securities, and restricted cash. Novavax second-quarter financial results
• Positive Sentiment: Sanofi’s collaboration remains a key potential catalyst: manufacturing technology transfer is expected to finish in mid-2027, which would trigger a $75 million milestone payment. Sanofi also plans to advance discussions with regulators on a Phase 3 COVID-19/influenza combination vaccine trial. Novavax lifts annual revenue forecast
• Neutral Sentiment: Management is increasingly focused on licensing its Matrix-M adjuvant and developing additional programs, including a potential C. difficile vaccine entering clinical development as early as 2027. These opportunities could diversify revenue but remain long-term and execution-dependent. Novavax Q2 2026 earnings call transcript
• Negative Sentiment: Revenue declined 76% year over year to $56.7 million, and Novavax posted a $53 million net loss versus $107 million of net income in the prior-year quarter. The results highlight the company’s continuing dependence on partnership payments as COVID-19 vaccine demand weakens. Novavax Q2 revenue falls 76 percent

Analyst Ratings Changes

Several equities research analysts recently commented on the company. TD Cowen raised their target price on Novavax from $8.00 to $9.00 and gave the company a “hold” rating in a report on Wednesday, May 6th. Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a report on Tuesday. BTIG Research reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research report on Thursday, June 11th. Wall Street Zen lowered shares of Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Finally, Zacks Research raised shares of Novavax from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $13.00.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.